Abstract
Drugs with a long residence time at their target sites are often more efficacious in disease treatment. The mechanism, however, behind prolonged retention at the site of action is often difficult to understand for non-covalent agents. In this context, we focus on epichaperome agents, such as zelavespib and icapamespib, which maintain target binding for days despite rapid plasma clearance, minimal retention in non-diseased tissues, and rapid metabolism. They have shown significant therapeutic value in cancer and neurodegenerative diseases by disassembling epichaperomes, which are assemblies of tightly bound chaperones and other factors that serve as scaffolding platforms to pathologically rewire protein–protein interactions. To investigate their impact on epichaperomes in vivo, we conducted pharmacokinetic and target occupancy measurements for zelavespib and monitored epichaperome assemblies biochemically in a mouse model. Our findings provide evidence of the intricate mechanism through which zelavespib modulates epichaperomes in vivo. Initially, zelavespib becomes trapped when epichaperomes bound, a mechanism that results in epichaperome disassembly, with no change in the expression level of epichaperome constituents. We propose that the initial trapping stage of epichaperomes is a main contributing factor to the extended on-target residence time observed for this agent in clinical settings. Zelavespib’s residence time in tumors seems to be dictated by target disassembly kinetics rather than by frank drug–target unbinding kinetics. The off-rate of zelavespib from epichaperomes is, therefore, much slower than anticipated from the recorded tumor pharmacokinetic profile or as determined in vitro using diluted systems. This research sheds light on the underlying processes that make epichaperome agents effective in the treatment of certain diseases.
Funding Information
  • NIH (RF1 AG071805, U01 AG032969, R01 CA172546, P01 CA186866, R01 AG072599, R56 AG061869, R01 AG067598, R01 AG074004, R56 AG072599, P30 CA08748, A2022020F)
  • William H. (RF1 AG071805, U01 AG032969, R01 CA172546, P01 CA186866, R01 AG072599, R56 AG061869, R01 AG067598, R01 AG074004, R56 AG072599, P30 CA08748, A2022020F)
  • Alice Goodwin (RF1 AG071805, U01 AG032969, R01 CA172546, P01 CA186866, R01 AG072599, R56 AG061869, R01 AG067598, R01 AG074004, R56 AG072599, P30 CA08748, A2022020F)
  • Commonwealth Foundation for Cancer Research (RF1 AG071805, U01 AG032969, R01 CA172546, P01 CA186866, R01 AG072599, R56 AG061869, R01 AG067598, R01 AG074004, R56 AG072599, P30 CA08748, A2022020F)
  • Experimental Therapeutics Center of MSKCC (RF1 AG071805, U01 AG032969, R01 CA172546, P01 CA186866, R01 AG072599, R56 AG061869, R01 AG067598, R01 AG074004, R56 AG072599, P30 CA08748, A2022020F)
  • BrightFocus Foundation (RF1 AG071805, U01 AG032969, R01 CA172546, P01 CA186866, R01 AG072599, R56 AG061869, R01 AG067598, R01 AG074004, R56 AG072599, P30 CA08748, A2022020F)

This publication has 64 references indexed in Scilit: